Discover
SLRN
Acelyrin, Inc.
2.27
undefined x undefined
undefined x undefined
bid
ask
+
2.27
0.00%
07:00 PM
| Ytd | -27.71% | |
| 1y | -47.21% |
day range
52 week range
| Open | Prev Close | Low | High | Mkt Cap | N/A | ||||
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -1.50 |
| Beta | N/A | Short Ratio | 11.83 | Inst. Own | 99.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 10.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.84 | -0.49 | 0.35 | 41.67% |
| 2024-08-13 | 2024-06 | -0.66 | -0.86 | -0.2 | -30.30% |
| 2024-08-13 | 2024-06 | -0.66 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.93 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.93 | -0.36 | 0.57 | 61.29% |
| 2024-03-28 | 2023-12 | -1 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2024-12-11 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-10-16 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2024-08-19 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2024-08-15 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
Profile
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-07-16 | BECKER DANIEL J | Director | 3.00K | Sale |
| 2023-05-08 | DIER MARDI C | Chief Financial Officer | 0.00 | Purchase |
| 2023-08-15 | GLORIA MELANIE | Chief Operating Officer | 140.58K | Stock Award(Grant) |
| 2023-05-08 | GOSEBRUCH HENRY O. | Director | 50.00K | Purchase |
| 2023-08-15 | KIM MINA | Officer | 119.68K | Stock Award(Grant) |
| 2024-03-31 | LIN SHAO-LEE | Chief Executive Officer | 3.45M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | T. Rowe Price Investment Management, Inc. | 10.43M | 33.17M | 10.40% |
| 2024-09-29 | Ayurmaya Capital Management Company, LP | 9.33M | 29.68M | 9.30% |
| 2024-09-29 | Citadel Advisors Llc | 6.52M | 20.74M | 6.50% |
| 2024-09-29 | Blackrock Inc. | 5.98M | 19.02M | 5.96% |
| 2024-09-29 | Millennium Management Llc | 5.49M | 17.45M | 5.47% |
| 2024-09-29 | Vanguard Group Inc | 4.07M | 12.93M | 4.05% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Price (T.Rowe) Small-Cap Value Fund | 2.84M | 9.03M | 2.83% |
| 2024-09-29 | Price (T.Rowe) Small Cap Stock Fund | 2.59M | 8.24M | 2.58% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.30M | 7.30M | 2.29% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.89M | 6.01M | 1.88% |
| 2024-09-29 | Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 1.50M | 4.76M | 1.49% |
| 2024-09-29 | Price (T.Rowe) Institutional Small-Cap Stock Fund | 1.28M | 4.07M | 1.28% |